Leerink Partnrs Has Pessimistic View of Geron Q2 Earnings
Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...
bovnews41m
Walgreens Boots Alliance Inc (WBA) Stock Posted a Gross Margin of 16.30% Over the Past Year: Is This Justifiable?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...
Hosted on MSN1d
Leerink Partners Upgrades Align Technology (ALGN)
Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...
Align Technology (NASDAQ:ALGN) Upgraded at Leerink Partnrs
Align Technology (NASDAQ:ALGN – Get Free Report) was upgraded by investment analysts at Leerink Partnrs from a “hold” rating ...
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing ...
bovnews1d
CureVac BV (CVAC) Stock Rated Market Perform by Leerink Partners
CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...
Third Rock-Backed Maze Therapeutics Reveals Profit in US IPO Filing
(Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of ...
Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...
uniQure Inc.: uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...